Description

Simple

A medication used to manage allergy symptoms such as itchy eyes and runny nose.

Clinical

A second generation antihistamine used to manage the symptoms of allergic rhinitis.

Overview

Loratadine is a second generation antihistamine used to manage symptoms of allergic rhinitis.[5] A lack of sedative and CNS adverse effects make loratadine, along with other second generation antihistamines, preferable over their 1st generation counterparts in many clinical situations.[7]

Pharmacology

Indication

Loratadine is a 2nd generation antihistamine and is used to manage symptoms of allergic rhinitis, wheal formation, urticaria, and other allergic dermatologic conditions.[ Read more

Pharmacodynamic

Like other 2nd generation antihistamines, loratadine is selective for peripheral H1 receptors.[ Read more

Mechanism of action

Histamine release is a key mediator in allergic rhinitis and urticaria.[12][ Read more

Absorption

Loratadine is rapidly absorbed and achieves peak plasma concentration in 1-2 hours, while it's main metabolite achieves peak plasma concentration in 3-4 hours.[ Read more

Protein binding

97 - 99% of the loratadine is bound to plasma proteins.[17]

Volume of distribution

The volume of distribution of loratadine is 120 L/Kg.[18]

Clearance

The clearance of loratadine after single oral doses of 20 mg and 40 mg are 12 L/h/kg and 9 L/h/kg respectively.[ Read more

Half life

The elimination half life is approximately 10 hours for loratadine and 20 hours for descarboethoxyloratadine.[6]

Route of elimination

Over a 10 day period, 40% of loratadine is excreted in the urine, and 42% is eliminated in the faeces.[17]

Toxicity

Second generation antihistamines such as loratadine have very few adverse effects; however, insomnia, headache, fatigue, drowsiness and rash have been reported.[ Read more

Adverse Effects

Effect Regions Age Groups Incidences Evidence Type
Sedation Canada
  • adult
  • Kind: experimental
    • Percent: 8
  • Kind: placebo
    • Percent: 6
  • Kind: comparator
    • Percent: 8
  • Kind: comparator
    • Percent: 22
  • Kind: comparator
    • Percent: 15
  • Clinical Trial
    Sedation US
    • pediatric
  • Kind: experimental
    • Percent: 5
  • Kind: experimental
    • Percent: 4
  • Kind: placebo
    • Percent: 5
  • Kind: comparator
    • Percent: 8
  • Kind: comparator
    • Percent: 11
  • Clinical Trial
    Headache Canada
  • Kind: experimental
    • Percent: 8
  • Kind: placebo
    • Percent: 11
  • Kind: comparator
    • Percent: 7
  • Clinical Trial
    Fatigue Canada
    • adult
  • Kind: experimental
    • Percent: 4
  • Kind: placebo
    • Percent: 4
  • Kind: comparator
    • Percent: 3
  • Kind: comparator
    • Percent: 9
  • Kind: comparator
    • Percent: 6
  • Clinical Trial
    Headache US
    • pediatric
  • Kind: experimental
    • Percent: 3
  • Kind: experimental
    • Percent: 6
  • Kind: placebo
    • Percent: 8
  • Kind: comparator
    • Percent: 4
  • Kind: comparator
    • Percent: 8
  • Clinical Trial
    Headache Canada
    • adult
  • Kind: experimental
    • Percent: 8
  • Kind: placebo
    • Percent: 6
  • Kind: comparator
    • Percent: 5
  • Kind: comparator
    • Percent: 8
  • Kind: comparator
    • Percent: 7
  • Clinical Trial
    Fatigue US
    • pediatric
  • Kind: experimental
    • Percent: 3
  • Kind: placebo
    • Percent: 2
  • Kind: comparator
    • Percent: 5
  • Clinical Trial
    Wheezing US
    • pediatric
  • Kind: experimental
    • Percent: 4
  • Kind: placebo
    • Percent: 2
  • Kind: comparator
    • Percent: 5
  • Clinical Trial
    Nausea US
    • pediatric
  • Kind: experimental
    • Percent: 4.35
  • Kind: experimental
    • Percent: 1.68
  • Kind: placebo
    • Percent: 2.98
  • Clinical Trial
    Dyspepsia US
    • pediatric
  • Kind: experimental
    • Percent: 4.35
  • Kind: experimental
    • Percent: 2.52
  • Kind: placebo
    • Percent: 1.79
  • Clinical Trial
    Vomiting US
    • pediatric
  • Kind: experimental
    • Percent: 4.35
  • Kind: experimental
    • Percent: 0
  • Kind: placebo
    • Percent: 0
  • Clinical Trial
    Nervousness US
    • pediatric
  • Kind: experimental
    • Percent: 4
  • Kind: placebo
    • Percent: 2
  • Kind: comparator
    • Percent: 2
  • Clinical Trial
    Nervousness US
    • pediatric
  • Kind: experimental
    • Percent: 4
  • Kind: experimental
    • Percent: 4
  • Kind: placebo
    • Percent: 1
  • Kind: comparator
    • Percent: 2
  • Kind: comparator
    • Percent: 2
  • Clinical Trial
    Fatigue Canada
  • Kind: experimental
    • Percent: 3
  • Kind: placebo
    • Percent: 3
  • Kind: comparator
    • Percent: 4
  • Clinical Trial
    Somnolence Canada
  • Kind: experimental
    • Percent: 4
  • Kind: placebo
    • Percent: 3
  • Kind: comparator
    • Percent: 4
  • Clinical Trial
    Dry Mouth Canada
    • adult
  • Kind: experimental
    • Percent: 4
  • Kind: placebo
    • Percent: 2
  • Kind: comparator
    • Percent: 1
  • Kind: comparator
    • Percent: 3
  • Kind: comparator
    • Percent: 3
  • Clinical Trial
    Rash US
    • pediatric
  • Kind: experimental
    • Percent: 2-3
  • Clinical Trial
    Earache US
    • pediatric
  • Kind: experimental
    • Percent: 2-3
  • Clinical Trial
    Pharyngitis US
    • pediatric
  • Kind: experimental
    • Percent: 2-3
  • Clinical Trial
    Influenza-like symptoms US
    • pediatric
  • Kind: experimental
    • Percent: 2-3
  • Clinical Trial
    Diarrhea US
    • pediatric
  • Kind: experimental
    • Percent: 2-3
  • Clinical Trial
    Tooth disorder US
    • pediatric
  • Kind: experimental
    • Percent: 2-3
  • Clinical Trial
    Epistaxis US
    • pediatric
  • Kind: experimental
    • Percent: 2-3
  • Clinical Trial
    Fatigue US
    • pediatric
  • Kind: experimental
    • Percent: 2-3
  • Clinical Trial
    Viral Infection US
    • pediatric
  • Kind: experimental
    • Percent: 2-3
  • Clinical Trial
    Stomatitis US
    • pediatric
  • Kind: experimental
    • Percent: 2-3
  • Clinical Trial
    Hyperkinesia US
    • pediatric
  • Kind: experimental
    • Percent: 3
  • Kind: placebo
    • Percent: 1
  • Kind: comparator
    • Percent: 1
  • Clinical Trial
    Hyperkinesia US
    • pediatric
  • Kind: experimental
    • Percent: 3
  • Kind: experimental
    • Percent: 0
  • Kind: placebo
    • Percent: 0.6
  • Kind: comparator
    • Percent: 0
  • Kind: comparator
    • Percent: 1
  • Clinical Trial
    Diarrhea US
    • pediatric
  • Kind: experimental
    • Percent: 0
  • Kind: experimental
    • Percent: 2.17
  • Kind: placebo
    • Percent: 0
  • Clinical Trial
    Dysphonia US
    • pediatric
  • Kind: experimental
    • Percent: 2
  • Kind: placebo
    • Percent: <1
  • Kind: comparator
    • Percent: 0
  • Clinical Trial
    Malaise US
    • pediatric
  • Kind: experimental
    • Percent: 2
  • Kind: placebo
    • Percent: 0
  • Kind: comparator
    • Percent: 1
  • Clinical Trial
    Conjunctivitis US
    • pediatric
  • Kind: experimental
    • Percent: 2
  • Kind: placebo
    • Percent: <1
  • Kind: comparator
    • Percent: 1
  • Clinical Trial
    Abdominal Pain US
    • pediatric
  • Kind: experimental
    • Percent: 2
  • Kind: placebo
    • Percent: 0
  • Kind: comparator
    • Percent: 0
  • Clinical Trial
    Upper Respiratory Tract Infection US
    • pediatric
  • Kind: experimental
    • Percent: 2
  • Kind: placebo
    • Percent: <1
  • Kind: comparator
    • Percent: 0
  • Clinical Trial
    Dry Mouth Canada
  • Kind: experimental
    • Percent: 2
  • Kind: placebo
    • Percent: 1
  • Kind: comparator
    • Percent: 2
  • Clinical Trial
    Abdominal Pain US
    • pediatric
  • Kind: experimental
    • Percent: 0
  • Kind: experimental
    • Percent: 1.68
  • Kind: placebo
    • Percent: 0
  • Clinical Trial
    Coughing Canada
    • adult
  • Kind: experimental
    • Percent: <1
  • Clinical Trial
    Dizziness Canada
    • adult
  • Kind: experimental
    • Percent: <1
  • Clinical Trial
    Appetite increased Canada
    • adult
  • Kind: experimental
    • Percent: <1
  • Clinical Trial
    Palpitations Canada
    • adult
  • Kind: experimental
    • Percent: <1
  • Clinical Trial
    Dryness of nose Canada
    • adult
  • Kind: experimental
    • Percent: <1
  • Kind: placebo
    • Percent: 0
  • Kind: comparator
    • Percent: <1
  • Kind: comparator
    • Percent: 0
  • Kind: comparator
    • Percent: <1
  • Clinical Trial
    Dry Eyes US
    Clinical Trial
    Dizziness Canada
    Post Marketing
    Anaphylaxis Canada
    Post Marketing
    Convulsions Canada
    Post Marketing
    Seizures Canada
    Post Marketing
    Tachycardia Canada
    Post Marketing
    Palpitations Canada
    Post Marketing
    Abnormal hepatic function Canada
    Post Marketing
    Alopecia Canada
    Post Marketing

    Contraindications

    • Route:
      • Oral
    • Hypersensitivity:
      • true
    • Regions: US

    Food Interactions

    Information currently not available.